Emerson Clinical Research Institute ( Site 0297)(4.6 mi away)Contact
+95 other location
This study will evaluate the safety, tolerability, and efficacy of Human Cytomegalovirus
(CMV) vaccine V160 administered in a 2-dose or 3-dose regimen in healthy seronegative women
16 to 35 years of age. Participants will receive blinded V160 on Day 1, Month 2, and Month 6
(3-dose regimen), V160 on Day 1 and Month 6 and placebo at Month 2 (2-dose regimen), or
placebo on Day 1, Month 2, and Month 6, and will be followed to approximately Month 36. The
primary hypothesis of the study is that administration of a 3-dose regimen of V160 will
reduce the incidence of primary CMV infection compared to placebo.
Clinical Study Identifier
Merck Sharp & Dohme Corp.
Last Modified on
12 August 2019
How clear was the trial content above?
Adding a note
Select a piece of text and start making personal notes.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.